Pandemic influenza A virus vaccines - CSL/NIAID

Drug Profile

Pandemic influenza A virus vaccines - CSL/NIAID

Alternative Names: Focetria (Mock-up); Foclivia; Influenza A virus H5N1/H9N2 subtypes vaccine - CSL/NIAID

Latest Information Update: 21 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases; Novartis
  • Developer CSL
  • Class Influenza A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Influenza A virus infections

Most Recent Events

  • 13 Jan 2010 Interim immunogenicity data from a clinical study in patients with end-stage renal disease released by SciCLone and Sigma-Tau
  • 24 Jul 2009 CHMP of the EMEA recommends approval of Foclivia®, a vaccine from Novartis that is a duplicate of Focetria® and consists of H5N1 virus surface antigens, in the European Union
  • 08 May 2007 Registered as mock-up vaccine for Influenza A virus infections in European Union (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top